Bell Investment Advisors’s Krystal Biotech KRYS Stock Holding History

Bell Investment Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.95K	Hold	16	–	–	﹤0.01%	911
2026 Q1	$4.13K	Hold	16	–	–	﹤0.01%	1042
2025 Q4	$3.94K	Hold	16	–	–	﹤0.01%	1074
2025 Q3	$2.83K	Sell	16 -3	-16%	-$449	﹤0.01%	1192
2025 Q2	$2.61K	Hold	19	–	–	﹤0.01%	1261
2025 Q1	$3.43K	Sell	19 -9	-32%	-$1.51K	﹤0.01%	1088
2024 Q4	$4.39K	Buy	28 +9	+47%	+$1.6K	﹤0.01%	984
2024 Q3	$3.46K	Buy	19 +6	+46%	+$1.16K	﹤0.01%	1112
2024 Q2	$2.39K	Sell	13 -1	-7%	-$168	﹤0.01%	1279
2024 Q1	$2.49K	Buy	+14	New	+$1.95K	﹤0.01%	1252
2023 Q4	–	Sell	-4	Closed	-$464	–	1958
2023 Q3	$464	Buy	+4	New	+$488	﹤0.01%	1824
2021 Q4	$1K	Buy	+9	New	+$524	﹤0.01%	1492

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bell Investment Advisors's KRYS Position: Q2 2026 in Review

Bell Investment Advisors held its Krystal Biotech (KRYS) position steady in Q2 2026 at 16 shares worth $5.95K. The position accounts for ﹤0.01% of the portfolio, ranked #911.

Bell Investment Advisors first reported a position in KRYS in Q4 2021 and has held it in 12 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Bell Investment Advisors held 16 shares of Krystal Biotech worth $5.95K as of Q2 2026.
Bell Investment Advisors left its Krystal Biotech share count unchanged in Q2 2026.
Krystal Biotech made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #911 holding.
Bell Investment Advisors first reported a position in Krystal Biotech in Q4 2021 and has held it in 12 quarters since.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.